Codexis (CDXS) Competitors $2.42 0.00 (0.00%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.49 +0.07 (+2.89%) As of 09/5/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDXS vs. GERN, RIGL, ZBIO, MYGN, VSTM, EBS, LXRX, XOMA, CBIO, and VNDAShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Geron (GERN), Rigel Pharmaceuticals (RIGL), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), Verastem (VSTM), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Codexis vs. Its Competitors Geron Rigel Pharmaceuticals Zenas BioPharma Myriad Genetics Verastem Emergent Biosolutions Lexicon Pharmaceuticals XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals Geron (NASDAQ:GERN) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability. Do insiders & institutionals have more ownership in GERN or CDXS? 73.7% of Geron shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 7.4% of Geron shares are held by insiders. Comparatively, 1.9% of Codexis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, GERN or CDXS? Codexis has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M11.60-$174.57M-$0.13-10.77Codexis$59.35M3.68-$65.28M-$0.83-2.92 Do analysts rate GERN or CDXS? Geron currently has a consensus target price of $4.19, indicating a potential upside of 199.11%. Codexis has a consensus target price of $11.00, indicating a potential upside of 354.55%. Given Codexis' higher possible upside, analysts clearly believe Codexis is more favorable than Geron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56Codexis 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer GERN or CDXS? In the previous week, Geron had 12 more articles in the media than Codexis. MarketBeat recorded 12 mentions for Geron and 0 mentions for Codexis. Codexis' average media sentiment score of 1.67 beat Geron's score of 1.51 indicating that Codexis is being referred to more favorably in the news media. Company Overall Sentiment Geron Very Positive Codexis Very Positive Which has more volatility and risk, GERN or CDXS? Geron has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Codexis has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Is GERN or CDXS more profitable? Geron has a net margin of -53.52% compared to Codexis' net margin of -113.67%. Geron's return on equity of -31.37% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Geron-53.52% -31.37% -16.01% Codexis -113.67%-105.83%-46.06% SummaryGeron beats Codexis on 11 of the 17 factors compared between the two stocks. Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$218.45M$3.18B$5.83B$9.93BDividend YieldN/A2.27%6.70%4.52%P/E Ratio-2.9221.1076.1526.11Price / Sales3.68466.44562.61123.62Price / CashN/A45.7236.9959.28Price / Book2.959.8711.486.09Net Income-$65.28M-$53.42M$3.29B$266.51M7 Day Performance-11.36%2.93%1.27%0.46%1 Month Performance-15.38%9.85%7.94%4.59%1 Year Performance-11.68%15.74%62.94%26.04% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis3.7574 of 5 stars$2.42flat$11.00+354.5%-13.9%$218.45M$59.35M-2.92250GERNGeron3.1068 of 5 stars$1.40-2.1%$4.19+199.1%-67.3%$893.22M$76.99M-10.77229RIGLRigel Pharmaceuticals2.6474 of 5 stars$38.85-1.2%$38.20-1.7%+208.3%$696.87M$179.28M7.18160Positive NewsShort Interest ↓ZBIOZenas BioPharma1.3991 of 5 stars$16.00-1.6%$36.67+129.2%N/A$673.77M$5M-4.51N/ATrending NewsAnalyst UpgradeAnalyst RevisionGap UpMYGNMyriad Genetics3.5504 of 5 stars$6.37+2.4%$12.45+95.5%-76.1%$592.69M$837.60M-1.492,700Positive NewsVSTMVerastem3.1934 of 5 stars$9.25+0.2%$13.29+43.6%+348.8%$569.29M$10K-2.8250EBSEmergent Biosolutions4.7869 of 5 stars$8.29-1.3%$14.33+73.0%-1.1%$442.81M$1.04B3.382,420News CoveragePositive NewsAnalyst ForecastLXRXLexicon Pharmaceuticals2.2027 of 5 stars$1.10-4.3%$3.23+193.2%-32.7%$399.74M$31.08M-3.33140Analyst ForecastXOMAXOMA Royalty3.6486 of 5 stars$32.47-0.7%$69.50+114.0%+32.4%$392.49M$28.49M-20.9510Positive NewsCBIOCrescent Biopharma3.5208 of 5 stars$14.40+1.8%$25.60+77.8%N/A$281.52M$10K-0.4150News CoverageVNDAVanda Pharmaceuticals4.1085 of 5 stars$4.73+0.6%$16.50+248.8%-9.3%$279.49M$198.77M-4.19290Positive News Related Companies and Tools Related Companies GERN Alternatives RIGL Alternatives ZBIO Alternatives MYGN Alternatives VSTM Alternatives EBS Alternatives LXRX Alternatives XOMA Alternatives CBIO Alternatives VNDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDXS) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
